Log in

NYSE:PBHPrestige Consumer Healthcare Competitors & Alternatives

$36.54
+0.93 (+2.61 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$35.21
Now: $36.54
$36.59
50-Day Range
$36.17
MA: $39.78
$44.07
52-Week Range
$27.40
Now: $36.54
$46.12
Volume368,000 shs
Average Volume494,712 shs
Market Capitalization$1.83 billion
P/E Ratio12.81
Dividend YieldN/A
Beta0.8

Competitors

Prestige Consumer Healthcare (NYSE:PBH) Vs. ASND, BHC, SDGR, JAZZ, RARE, and ZLAB

Should you be buying PBH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Prestige Consumer Healthcare, including Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), PPD (SDGR), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), and Zai Lab (ZLAB).

Prestige Consumer Healthcare (NYSE:PBH) and Ascendis Pharma A/S (NASDAQ:ASND) are both consumer discretionary companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Prestige Consumer Healthcare and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prestige Consumer Healthcare14.77%13.33%4.35%
Ascendis Pharma A/S-2,231.94%-36.56%-32.40%

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

100.0% of Ascendis Pharma A/S shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Prestige Consumer Healthcare and Ascendis Pharma A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$963.01 million1.90$142.28 million$2.9612.34
Ascendis Pharma A/S$14.98 million438.80$-244,180,000.00($5.25)-26.09

Prestige Consumer Healthcare has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Prestige Consumer Healthcare and Ascendis Pharma A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prestige Consumer Healthcare05202.29
Ascendis Pharma A/S001103.00

Prestige Consumer Healthcare presently has a consensus target price of $66.8333, indicating a potential upside of 87.68%. Ascendis Pharma A/S has a consensus target price of $172.2727, indicating a potential upside of 25.77%. Given Prestige Consumer Healthcare's higher possible upside, equities research analysts clearly believe Prestige Consumer Healthcare is more favorable than Ascendis Pharma A/S.

Summary

Prestige Consumer Healthcare beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

Prestige Consumer Healthcare (NYSE:PBH) and Bausch Health Companies (NYSE:BHC) are both consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and Bausch Health Companies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$963.01 million1.90$142.28 million$2.9612.34
Bausch Health Companies$8.60 billion0.71$-1,788,000,000.00$4.433.88

Prestige Consumer Healthcare has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prestige Consumer Healthcare and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prestige Consumer Healthcare14.77%13.33%4.35%
Bausch Health Companies-21.96%84.58%4.68%

Volatility & Risk

Prestige Consumer Healthcare has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Prestige Consumer Healthcare and Bausch Health Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prestige Consumer Healthcare05202.29
Bausch Health Companies151002.56

Prestige Consumer Healthcare presently has a consensus target price of $66.8333, suggesting a potential upside of 87.68%. Bausch Health Companies has a consensus target price of $30.9412, suggesting a potential upside of 80.42%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Bausch Health Companies.

Institutional and Insider Ownership

68.9% of Bausch Health Companies shares are owned by institutional investors. 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bausch Health Companies beats Prestige Consumer Healthcare on 9 of the 14 factors compared between the two stocks.

PPD (NASDAQ:SDGR) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Insider and Institutional Ownership

34.9% of PPD shares are owned by institutional investors. 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for PPD and Prestige Consumer Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PPD02102.33
Prestige Consumer Healthcare05202.29

PPD currently has a consensus price target of $59.6667, suggesting a potential downside of 35.40%. Prestige Consumer Healthcare has a consensus price target of $66.8333, suggesting a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than PPD.

Profitability

This table compares PPD and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PPDN/AN/AN/A
Prestige Consumer Healthcare14.77%13.33%4.35%

Valuation & Earnings

This table compares PPD and Prestige Consumer Healthcare's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PPD$85.54 million68.35N/AN/AN/A
Prestige Consumer Healthcare$963.01 million1.90$142.28 million$2.9612.34

Prestige Consumer Healthcare has higher revenue and earnings than PPD.

Summary

Prestige Consumer Healthcare beats PPD on 7 of the 10 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Volatility and Risk

Jazz Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares Jazz Pharmaceuticals and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals12.81%21.66%11.90%
Prestige Consumer Healthcare14.77%13.33%4.35%

Earnings & Valuation

This table compares Jazz Pharmaceuticals and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion2.73$523.37 million$14.607.30
Prestige Consumer Healthcare$963.01 million1.90$142.28 million$2.9612.34

Jazz Pharmaceuticals has higher revenue and earnings than Prestige Consumer Healthcare. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Prestige Consumer Healthcare, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals051302.72
Prestige Consumer Healthcare05202.29

Jazz Pharmaceuticals currently has a consensus target price of $157.1765, indicating a potential upside of 47.45%. Prestige Consumer Healthcare has a consensus target price of $66.8333, indicating a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Jazz Pharmaceuticals.

Insider and Institutional Ownership

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Prestige Consumer Healthcare on 12 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Profitability

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-348.78%-60.65%-40.51%
Prestige Consumer Healthcare14.77%13.33%4.35%

Earnings & Valuation

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million49.61$-402,730,000.00($7.36)-11.72
Prestige Consumer Healthcare$963.01 million1.90$142.28 million$2.9612.34

Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and Prestige Consumer Healthcare, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical031302.81
Prestige Consumer Healthcare05202.29

Ultragenyx Pharmaceutical currently has a consensus target price of $81.3571, indicating a potential downside of 5.68%. Prestige Consumer Healthcare has a consensus target price of $66.8333, indicating a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Ultragenyx Pharmaceutical.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Zai Lab and Prestige Consumer Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zai Lab00603.00
Prestige Consumer Healthcare05202.29

Zai Lab currently has a consensus price target of $81.25, suggesting a potential downside of 6.58%. Prestige Consumer Healthcare has a consensus price target of $66.8333, suggesting a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Zai Lab.

Profitability

This table compares Zai Lab and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zai LabN/AN/AN/A
Prestige Consumer Healthcare14.77%13.33%4.35%

Valuation & Earnings

This table compares Zai Lab and Prestige Consumer Healthcare's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$12.98 million389.29$-195,070,000.00($3.03)-28.70
Prestige Consumer Healthcare$963.01 million1.90$142.28 million$2.9612.34

Prestige Consumer Healthcare has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

78.3% of Zai Lab shares are owned by institutional investors. 1.2% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Zai Lab has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Summary

Prestige Consumer Healthcare beats Zai Lab on 9 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.9$136.97+2.2%$6.57 billion$14.98 million-25.70Analyst Downgrade
Analyst Revision
Heavy News Reporting
Bausch Health Companies logo
BHC
Bausch Health Companies
2.5$17.19+0.2%$6.09 billion$8.60 billion-3.21Analyst Report
Increase in Short Interest
Heavy News Reporting
SDGR
PPD
0.9$92.36+1.1%$5.92 billion$85.54 million0.00
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.0$106.60+1.1%$5.84 billion$2.16 billion22.16
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.5$86.26+2.0%$5.25 billion$103.71 million-11.74Analyst Upgrade
Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.1$86.97+2.9%$5.20 billion$12.98 million-28.70Analyst Report
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$154.40+1.1%$5.19 billion$26.52 million-15.69
United Therapeutics logo
UTHR
United Therapeutics
1.7$117.44+0.4%$5.15 billion$1.45 billion9.79Analyst Downgrade
Insider Selling
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
0.9$114.93+0.8%$5.05 billion$3.34 million-17.71Heavy News Reporting
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.4$94.48+0.1%$4.95 billion$1.11 billion72.68
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.4$44.51+1.3%$4.60 billion$168.80 million494.61Heavy News Reporting
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.3$74.14+2.4%$4.44 billionN/A-5.87Insider Selling
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$24.03+1.6%$4.35 billion$114.62 million-9.21Insider Selling
Heavy News Reporting
Myokardia logo
MYOK
Myokardia
1.4$93.13+2.3%$4.35 billion$33.56 million-13.96Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.6$78.97+0.8%$4.28 billion$66.51 million-10.63Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$71.12+2.5%$4.23 billion$2.11 million-14.60Analyst Downgrade
Increase in Short Interest
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.53+1.9%$4.08 billion$182.24 million-11.95Insider Selling
GW Pharmaceuticals PLC- logo
GWPH
GW Pharmaceuticals PLC-
1.6$127.90+0.2%$3.98 billion$311.33 million130.51Insider Selling
BBIO
BridgeBio Pharma
1.6$31.58+2.0%$3.94 billion$40.56 million-12.73
HUTCHISON CHINA/S logo
HCM
HUTCHISON CHINA/S
1.0$28.46+3.3%$3.92 billion$204.89 million-35.58Analyst Upgrade
FibroGen logo
FGEN
FibroGen
2.1$41.77+0.1%$3.73 billion$256.58 million-31.64Analyst Upgrade
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$54.98+3.5%$3.72 billion$306.98 million-11.02Insider Selling
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$52.90+0.9%$3.68 billion$117.91 million-9.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$59.70+1.0%$3.65 billion$36.13 million-54.77Insider Selling
Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$65.92+0.3%$3.31 billion$806.43 million-10.20Heavy News Reporting
Allakos logo
ALLK
Allakos
1.1$68.38+1.9%$3.27 billionN/A-34.36Analyst Downgrade
Alkermes logo
ALKS
Alkermes
1.1$20.04+1.8%$3.18 billion$1.17 billion-22.77
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.7$54.24+0.9%$3.06 billion$25 million-12.03Analyst Downgrade
Increase in Short Interest
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
2.2$83.04+1.2%$3.04 billionN/A-32.44
Insmed logo
INSM
Insmed
1.5$27.84+0.5%$2.83 billion$136.47 million-9.87Analyst Upgrade
Opko Health logo
OPK
Opko Health
1.7$4.02+0.0%$2.69 billion$901.90 million-8.38Analyst Report
Increase in Short Interest
Heavy News Reporting
TG Therapeutics logo
TGTX
TG Therapeutics
1.7$23.76+1.6%$2.66 billion$150,000.00-11.70Analyst Downgrade
Amarin logo
AMRN
Amarin
1.8$6.72+1.2%$2.56 billion$429.76 million-112.00
KRTX
Karuna Therapeutics
1.5$96.38+1.5%$2.56 billionN/A-0.66Insider Selling
Increase in Short Interest
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$65.13+0.0%$2.49 billion$644.77 million10.24Decrease in Short Interest
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$57.80+0.5%$2.42 billion$421.03 million-2,888.56Analyst Upgrade
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.7$32.45+2.2%$2.40 billionN/A-5.17Increase in Short Interest
SAGE Therapeutics logo
SAGE
SAGE Therapeutics
1.6$42.92+2.9%$2.29 billion$6.87 million-3.45
IGMS
IGM Biosciences
1.5$71.65+0.7%$2.19 billionN/A-14.93Analyst Downgrade
TPTX
Turning Point Therapeutics
1.6$60.38+0.1%$2.17 billionN/A-16.77Analyst Report
Analyst Revision
Heavy News Reporting
Uniqure logo
QURE
Uniqure
1.7$46.41+2.7%$2.11 billion$7.28 million-15.42Analyst Downgrade
Principia Biopharma logo
PRNB
Principia Biopharma
1.4$64.03+7.9%$1.95 billion$35.16 million-26.24
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.0$16.50+1.5%$1.92 billion$306.49 million18.75
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$48.25+1.2%$1.88 billion$26.69 million-36.55Analyst Upgrade
Insider Selling
Heavy News Reporting
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.7$24.89+2.0%$1.88 billion$23.90 million-14.73Insider Selling
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.6$31.87+0.3%$1.82 billion$156.70 million-29.78Analyst Report
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$115.06+2.5%$1.80 billion$120.28 million-33.45Analyst Downgrade
Unusual Options Activity
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$14.88+2.5%$1.72 billion$320,000.00-11.36Analyst Downgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.9$18.01+3.8%$1.68 billionN/A-5.34Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$103.91+3.6%$1.66 billionN/A-15.26Analyst Downgrade
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.